Technologies for MHC class I immunoproteomics : Current status of cancer proteomics, how far are we from clinical applicationHOPPES, Rieuwert; EKKEBUS, Reggy; SCHUMACHER, Ton N. M et al.Journal of proteomics (Print). 2010, Vol 73, Num 10, pp 1945-1953, issn 1874-3919, 9 p.Article

Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132CRAWFORD, Lisa J. A; WALKER, Brian; OVAA, Huib et al.Cancer research (Baltimore). 2006, Vol 66, Num 12, pp 6379-6386, issn 0008-5472, 8 p.Article

CEP-18770 : A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomibPIVA, Roberto; RUGGERI, Bruce; PEZZONI, Gabriella et al.Blood. 2008, Vol 111, Num 5, pp 2765-2775, issn 0006-4971, 11 p.Article

Reactive glia show increased immunoproteasome activity in Alzheimer's diseaseORRE, Marie; KAMPHUIS, Willem; OVAA, Huib et al.Brain. 2013, Vol 136, pp 1415-1431, issn 0006-8950, 17 p., 5Article

Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathyBIRKS, Emma J; LATIF, Najma; YACOUB, Magdi H et al.Cardiovascular research. 2008, Vol 79, Num 3, pp 472-480, issn 0008-6363, 9 p.Article